MédiMabs employs a royalty-based compensation program to facilitate the licensing, producing and marketing of existing monoclonal antibodies and de novo generated antibodies. Our policy is one of direct dialogue between suppliers and customers, thus rendering the process as rewarding to academic institutions and research in general.
MédiMabs understands that much time and effort is expended in the development of antibodies in research laboratories. However, although these agents are valuable and have a definite commercial potential within the same research community, only a small percentage of these are adequately exploited.
MédiMabs has consequently devised a royalty-based compensation program to facilitate the licensing and the marketing of such antibodies, thus rendering the licensing process a rewarding one for academic institutions and research in general.
MédiMabs' policy is one of direct dialogue with suppliers (Academic and industrial Technology Transfer Offices, researchers etc.) and customers (academic and industrial researchers).